List of Excipients in Branded Drug KENGREAL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Chiesi USA Inc	KENGREAL	cangrelor	10122-620	MANNITOL
Chiesi USA Inc	KENGREAL	cangrelor	10122-620	SODIUM HYDROXIDE
Chiesi USA Inc	KENGREAL	cangrelor	10122-620	SORBITOL

KENGREAL Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: September 24, 2026

KENGREAL is an intravenous cangrelor product used during percutaneous coronary intervention. Its formulation is deliberately simple: cangrelor tetrasodium, mannitol, and sodium hydroxide for pH adjustment. The commercial opportunity is therefore less likely to come from adding conventional excipients and more likely to come from improving reconstitution, ready-to-use delivery, storage, container compatibility, and hospital workflow.

KENGREAL is a small-molecule antiplatelet drug, not a biologic. Biosimilar regulation does not apply. A competing product would most likely use an abbreviated new drug application, a 505(b)(2) application, or a full NDA depending on its formulation, labeling, and reliance strategy.

What is KENGREAL and how is its formulation designed?

KENGREAL contains cangrelor, an intravenous P2Y12 platelet inhibitor. The FDA-approved product is supplied as a sterile lyophilized powder in a single-dose vial. The formulation is reconstituted and then diluted for intravenous administration.[1]

Attribute	KENGREAL profile
Active ingredient	Cangrelor tetrasodium
Dosage form	Lyophilized powder for solution
Route	Intravenous
Approved use	Adjunct to PCI
Standard dose	30 mcg/kg IV bolus followed by 4 mcg/kg/min infusion
Primary excipients	Mannitol and sodium hydroxide
Reconstitution	Sterile water for injection
Further dilution	Compatible intravenous diluents identified in labeling
Administration setting	Hospital, cath laboratory, procedural care
Regulatory category	Small-molecule drug
Biosimilar pathway	Not applicable

The formulation has two core technical requirements. It must support rapid reconstitution in an acute-care environment, and it must maintain chemical stability during the bolus and infusion period. KENGREAL is not intended for prolonged refrigerated dispensing in the manner of many biologics.

Which excipients are used in KENGREAL?

KENGREAL uses mannitol as the principal formulation excipient and sodium hydroxide for pH adjustment.[1]

Mannitol

Mannitol is likely used as a bulking and cake-forming agent in the lyophilized product. In an injectable freeze-dried formulation, mannitol can improve cake structure, support manufacturing yield, and provide a visually consistent vial after lyophilization.

Mannitol is also attractive because it has a long history in parenteral products and does not introduce the protein-stabilization issues associated with surfactants, amino acids, or complex carbohydrate systems.

Its limitations include:

• Potential crystallization during freezing or storage.
• Possible impact on cake morphology.
• Osmolality contribution after reconstitution.
• Limited ability to solve chemical degradation of cangrelor by itself.
• A need for tight control of moisture and residual water.

For a competitor, replacing mannitol with sucrose, trehalose, glycine, lactose, or another bulking system would require comparative work on stability, cake appearance, reconstitution time, particulate matter, container closure integrity, and compatibility with the infusion solution.

Sodium hydroxide

Sodium hydroxide is used to adjust formulation pH. It is not expected to be the main differentiating excipient. Its commercial significance is that pH may affect cangrelor stability, solubility, degradation pathways, and compatibility with the final diluted infusion.

A formulation strategy that changes buffer capacity or pH could create a meaningful product difference, but it would also trigger a larger regulatory burden. A new buffer system would need data covering:

• Long-term and accelerated stability.
• Degradation products.
• Reconstitution performance.
• Dilution compatibility.
• Container interaction.
• Infusion-line compatibility.
• Hemolysis and local tolerance.
• Particulate formation.

Why KENGREAL does not need a complex excipient platform

Cangrelor is administered intravenously and is used for short-duration platelet inhibition. It does not require a depot system, absorption enhancer, sustained-release matrix, lipid vehicle, or protein-stabilization package.

That limits the technical value of adding excipients. The strongest product opportunities are operational rather than pharmacological.

What formulation opportunities exist for KENGREAL competitors?

The largest opportunity is to remove or reduce the hospital preparation burden.

Ready-to-use liquid presentation

A ready-to-use cangrelor solution could eliminate vial reconstitution and reduce preparation time. Potential formats include:

• Single-use infusion bags.
• Small-volume ready-to-administer bottles.
• Prefilled syringes for bolus dosing.
• Dual-chamber containers separating drug and diluent.
• Pharmacy-compounded premix formats.

A ready-to-use product would need to address the short procedural window in which KENGREAL is used. The relevant value proposition is reduced preparation error, not extended outpatient shelf life.

Key development questions include whether cangrelor remains stable in a premixed solution, whether the formulation tolerates common infusion materials, and whether the product can maintain acceptable particulate and potency specifications.

Longer in-use stability

KENGREAL is used in a setting where the product may be reconstituted shortly before administration. Extending post-reconstitution or post-dilution stability could reduce waste and improve pharmacy workflow.

A commercially useful product could target:

• A longer refrigerated shelf life after reconstitution.
• A longer room-temperature in-use period.
• Greater tolerance to delays between pharmacy preparation and PCI.
• Reduced need to discard unused infusion material.

The value is highest in hospitals with variable procedure schedules or centralized pharmacy preparation.

Improved reconstitution

A formulation that reconstitutes faster and with less foaming could compete on workflow. Potential approaches include:

• Modified lyophilized cake structure.
• Different bulking-agent ratios.
• Controlled residual moisture.
• Improved vial geometry.
• Optimized vacuum and stopper configuration.
• Lower fill volume.
• A soluble or spray-dried presentation.

Reconstitution time should be measured under actual cath-laboratory conditions, not only in controlled laboratory testing.

Reduced vial count

KENGREAL is weight-based. Larger vial sizes or concentrated presentations could reduce the number of vials required for heavier patients or high-volume procedural centers.

The tradeoff is dose waste. A larger vial may improve preparation efficiency but increase unused drug when the patient dose is small. A portfolio containing multiple vial strengths could improve utilization but add manufacturing and inventory complexity.

Device-enabled administration

A prefilled syringe for the bolus portion could reduce dose-calculation and transfer steps. A separate infusion container could provide the maintenance dose.

A combined bolus-and-infusion kit may be commercially attractive if it simplifies emergency use. The kit could include:

• A premeasured bolus syringe.
• A premixed infusion bag.
• A barcode-enabled package.
• Standardized instructions for weight-based dosing.
• Administration tubing validated for the product.

The regulatory classification would depend on the degree of integration and the claims made for the kit.

What manufacturing and intellectual-property barriers affect excipient competition?

The active ingredient is the primary technical barrier. Cangrelor synthesis requires control of stereochemistry, impurity profile, salt form, residual solvents, and degradation products. A competitor must also establish a reproducible sterile injectable process.

Manufacturing barriers

Important manufacturing issues include:

Area	Commercial risk
Active pharmaceutical ingredient	Complex synthesis and impurity control
Salt form	Impact on solubility, stability, and assay
Sterile fill-finish	High sensitivity to particulate and microbial controls
Lyophilization	Cycle development and cake consistency
Container closure	Moisture and oxygen protection
Reconstitution	Time, clarity, and visible particles
Dilution	Compatibility with hospital diluents and tubing
Packaging	Protection from moisture and handling damage

A competitor using the same excipient profile may reduce formulation risk but have less room for composition-of-matter differentiation. A competitor using a new excipient system may create a differentiated formulation but face a larger clinical and regulatory package.

Patent strategy

Excipient changes do not automatically avoid active-ingredient, formulation, process, or method-of-use patents. A freedom-to-operate review must separate:

1. Cangrelor composition and salt patents.
2. Pharmaceutical composition patents.
3. Lyophilization and manufacturing-process patents.
4. Reconstitution and dilution claims.
5. PCI-related method-of-use claims.
6. Container, device, or kit claims.

The FDA label identifies KENGREAL as NDA 207137.[1] The Orange Book should be reviewed for current listed patents, exclusivity codes, and any changes to the listed patent record.[2] Patent expiry cannot be inferred solely from the product launch date because patent term adjustment, patent-term extension, terminal disclaimers, and pediatric exclusivity may alter the effective date.

When does KENGREAL lose exclusivity?

KENGREAL received FDA approval in 2015. Its five-year new chemical entity exclusivity period therefore ran from approval and did not create a permanent barrier to abbreviated applications.[1,3]

The main commercial barriers after NCE exclusivity are patent scope, regulatory data requirements, manufacturing capability, and hospital adoption. Cangrelor is not subject to biosimilar exclusivity because it is a chemically synthesized small molecule.

Exclusivity issue	KENGREAL position
New chemical entity exclusivity	Five years from FDA approval
Orphan exclusivity	No orphan exclusivity identified for the PCI indication
Biologic exclusivity	Not applicable
Pediatric exclusivity	Must be confirmed from current FDA records
Paragraph IV risk	Depends on current Orange Book patent listings
Generic pathway	Potential ANDA route, subject to listed patents and equivalence
505(b)(2) pathway	Potential route for materially different formulation or presentation

What is the Orange Book status of KENGREAL?

KENGREAL is listed as an FDA-approved prescription drug under NDA 207137.[1] The commercial relevance of its Orange Book status depends on whether patents are listed against the NDA and whether those patents cover the active ingredient, formulation, method of use, or drug-delivery presentation.

An ANDA applicant would need to evaluate:

• Paragraph I certification if no patent information is listed.
• Paragraph II certification if the listed patent has expired.
• Paragraph III certification if the applicant accepts approval after patent expiry.
• Paragraph IV certification if the applicant asserts that a listed patent is invalid, unenforceable, or not infringed.
• A section viii statement for a method-of-use patent where the applicant omits the patented indication.

The practical risk is highest where a formulation or method-of-use patent covers the commercial product and the applicant cannot carve out the protected indication.

Which companies are challenging KENGREAL exclusivity?

No biosimilar challenger is relevant. Any serious competitive challenge would come from a generic-drug manufacturer, a specialty injectable company, or a 505(b)(2) developer.

Publicly visible competition should be assessed through:

• FDA Orange Book patent listings.
• FDA ANDA approvals.
• Paragraph IV litigation databases.
• Federal district court filings.
• USPTO assignment and maintenance records.
• FDA drug-shortage and product-availability databases.

The absence of a marketed generic does not establish that no ANDA has been filed. ANDA filings are generally confidential before approval or litigation disclosure.

What patent litigation and settlement risks affect KENGREAL?

A Paragraph IV challenge could generate litigation under the Hatch-Waxman framework. The key commercial events would be:

1. Notice of Paragraph IV certification.
2. NDA-holder litigation within the statutory period.
3. Possible 30-month stay of approval.
4. Claim construction and validity proceedings.
5. Settlement involving a licensed entry date.
6. Approval or launch before patent expiry if the challenger prevails.

Settlement terms may include an authorized-generic arrangement, a delayed-entry license, supply rights, or restrictions tied to a particular indication. Any entry date should be treated as transaction-specific until confirmed in a public filing or FDA record.

For an excipient-focused challenger, the strongest position may be a design-around that avoids composition claims while retaining bioequivalence and the labeled PCI use.

How strong is the KENGREAL formulation estate?

The formulation estate is likely more vulnerable than an estate built around a complex delivery technology because KENGREAL uses a small number of conventional parenteral excipients.

Strength factors include:

• A narrow and well-defined pH range.
• Specific cangrelor-to-mannitol ratios.
• Stability claims tied to lyophilization.
• Reconstitution or dilution claims.
• Container-closure or oxygen-control claims.
• Claims covering a ready-to-use formulation.
• Method claims linked to bridging from oral P2Y12 therapy.

Weakness factors include:

• Conventional excipient selection.
• A simple injectable composition.
• Multiple plausible bulking agents.
• The availability of standard parenteral development techniques.
• The possibility of designing around specific ratio or pH claims.

The strongest commercial patent position would likely come from a technically difficult presentation, such as a stable ready-to-use liquid or an integrated bolus-and-infusion system, rather than from a basic substitution of mannitol with another bulking agent.

What FDA regulatory pathway is best for a new KENGREAL formulation?

The pathway depends on the extent of formulation change.

Product concept	Likely pathway
Same active, same route, same dosage form, pharmaceutically equivalent	ANDA
Same active with meaningful formulation or device difference	505(b)(2) NDA
New indication or materially different clinical use	NDA or supplemental NDA
Combination kit with administration device	ANDA or 505(b)(2), depending on claims
New chemical entity	Full NDA, not commercially relevant to an excipient redesign

An ANDA strategy is strongest where the product can demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy FDA requirements for an injectable product. A 505(b)(2) strategy may be more practical for a premixed solution, new container system, altered concentration, or presentation that cannot rely entirely on the reference product.

How does KENGREAL compare with competing antiplatelet options?

KENGREAL competes with oral P2Y12 inhibitors and intravenous GP IIb/IIIa inhibitors, but its direct differentiation is rapid intravenous action and rapid offset.

Product category	Main advantage	Excipient opportunity
KENGREAL	Immediate IV platelet inhibition during PCI	Reconstitution, premix, device integration
Clopidogrel	Low cost and oral administration	Limited injectable opportunity
Prasugrel	Potent oral therapy	Limited excipient differentiation
Ticagrelor	Oral, reversible P2Y12 inhibition	Oral formulation and adherence
GP IIb/IIIa inhibitors	Potent IV platelet inhibition	Infusion stability and dosing systems

A new cangrelor product would need to compete on preparation speed, availability, dosing accuracy, waste reduction, and hospital procurement economics. A conventional excipient change alone is unlikely to change physician prescribing.

What commercial opportunities exist for KENGREAL excipients and delivery systems?

The most credible opportunities are hospital-use improvements:

Premixed infusion

A premixed infusion can reduce pharmacy compounding, shorten administration time, and lower preparation errors. It may also support standardized inventory management across cath labs and emergency departments.

Bolus syringe

A prefilled bolus syringe could reduce dose-transfer steps. The main development issue is weight-based dosing. The product may need several syringe strengths or a concentration that allows simple volume calculation.

Dual-chamber system

A dual-chamber container could separate cangrelor from the diluent until use. This format may combine extended shelf life with rapid activation, but it introduces device and combination-product validation requirements.

Lower-waste vial architecture

A vial optimized for typical PCI doses could improve drug utilization. A portfolio of vial sizes may be more commercially valuable than a single high-strength vial.

Hospital compatibility package

A differentiated product could include validated compatibility with commonly used tubing, filters, syringes, and infusion pumps. These data can support formulary adoption even when the active drug is unchanged.

What revenue exposure exists for KENGREAL?

KENGREAL revenue is exposed to PCI procedure volumes, hospital formulary decisions, supply reliability, and competition from oral antiplatelet therapy. Product-level sales may not be separately disclosed by the current commercial owner, Chiesi USA, making an independent KENGREAL revenue estimate unreliable without company reporting.

The value of an excipient or presentation improvement should therefore be modeled against:

• Number of PCI procedures.
• Share of procedures using intravenous P2Y12 inhibition.
• Average dose and vial utilization.
• Hospital acquisition price.
• Waste rate.
• Pharmacy labor savings.
• Reduction in preparation errors.
• Product availability during supply disruptions.

A ready-to-use product may command a premium if it reduces labor and waste. The premium will be limited if hospitals treat cangrelor as a low-volume rescue or bridge product and continue to purchase on price.

What generic launch scenarios exist for KENGREAL?

Three launch scenarios are plausible:

Scenario	Description	Commercial effect
Formulation-equivalent generic	Lyophilized vial with similar excipients	Highest price pressure
Excipient-different injectable	Same active with alternative stabilizer or bulking agent	Moderate differentiation, greater regulatory burden
505(b)(2) ready-to-use product	Premixed liquid, syringe, or dual-chamber system	Potential premium and workflow advantage

The first entrant could gain hospital contracts if it offers reliable supply and comparable preparation performance. A second entrant would likely intensify price competition unless it has a differentiated delivery system.

What are the key geographic opportunities?

The United States is the most structured market for an excipient-based KENGREAL challenge because of the Orange Book, ANDA, and 505(b)(2) pathways. Europe and other markets require separate assessment of:

• National and regional patent rights.
• Marketing authorization requirements.
• Hospital procurement systems.
• Reference-product exclusivity.
• Stability data requirements.
• Local packaging and language rules.
• Reimbursement for PCI use.

A global strategy should not assume that an FDA-approved excipient system will receive identical treatment elsewhere. Premixed products may have particular value in markets with centralized hospital pharmacies, while vial presentations may remain preferred where cold-chain and procurement costs dominate.

Key Takeaways

• KENGREAL uses a simple injectable formulation based on cangrelor tetrasodium, mannitol, and sodium hydroxide.
• Mannitol is the main formulation excipient and likely supports lyophilized cake structure.
• Sodium hydroxide primarily adjusts pH and is unlikely to provide meaningful commercial differentiation alone.
• The strongest opportunities are ready-to-use liquids, prefilled bolus syringes, dual-chamber systems, faster reconstitution, and reduced vial waste.
• KENGREAL is a small-molecule drug, so biosimilar competition is not relevant.
• Generic competition may proceed through an ANDA, while materially different presentations may use the 505(b)(2) pathway.
• Excipient changes do not by themselves avoid active-ingredient, formulation, process, or method-of-use patents.
• Product-level KENGREAL revenue is not separately transparent in public company reporting, so commercial modeling should use procedure volume, hospital adoption, waste, and preparation-cost assumptions.
• A conventional generic is likely to compete primarily on price. A ready-to-use product has a stronger basis for premium positioning.

FAQs

Can mannitol be replaced in a generic KENGREAL formulation?

Yes, in principle. A replacement excipient would require support for stability, lyophilization performance, reconstitution, particulate control, compatibility, and injectable safety. The change could also affect the regulatory pathway and patent analysis.

Could KENGREAL be sold as a premixed infusion?

Potentially. A premixed product would need adequate stability in the selected diluent and container system, along with validated in-use conditions, infusion compatibility, sterility, and particulate controls.

Is cangrelor eligible for a biosimilar application?

No. Cangrelor is a chemically synthesized small molecule. A competing product would generally use an ANDA, 505(b)(2) NDA, or full NDA rather than the biosimilar pathway.

Would a different excipient avoid KENGREAL patents?

Not necessarily. Patent claims may cover the active ingredient, salt form, concentration, manufacturing process, method of use, or a broader pharmaceutical composition. A different excipient is only useful if the resulting product falls outside enforceable claim scope.

What is the most commercially attractive KENGREAL formulation improvement?

A ready-to-use bolus-and-infusion system is likely the strongest opportunity because it can reduce preparation steps, dosing errors, pharmacy labor, and wasted product. Its value depends on achieving adequate stability without creating excessive device or manufacturing cost.

References

1. U.S. Food and Drug Administration. (2024). KENGREAL (cangrelor) for injection: Prescribing information. Chiesi USA, Inc.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2024). Drugs@FDA: KENGREAL, NDA 207137.